Hunan Cancer Hospital
133
41
49
24
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.8%
1 terminated/withdrawn out of 133 trials
96.0%
+9.4% vs industry average
19%
25 trials in Phase 3/4
0%
0 of 24 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (133)
Precision Navigation to Improve Community Cancer Screening Participation
Role: lead
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
Role: collaborator
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
Role: collaborator
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Role: collaborator
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
Role: collaborator
Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile Cancer
Role: collaborator
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Role: collaborator
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
Role: collaborator
A Comparative Study of Delayed Endoscopic DTI and Autologous Flap Reconstruction Post-Mastectomy
Role: collaborator
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Role: collaborator
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
Role: lead
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
Role: collaborator
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
Role: lead
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
Role: lead
Precision Antithrombotic Therapy
Role: collaborator
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
Role: collaborator
RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma
Role: collaborator
Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer
Role: lead
Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC
Role: collaborator
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Role: collaborator